Holen Sie sich die Stockscreener-App
1.32
2.33%
0.03
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex
Taking the lead: Biofrontera Inc (BFRI) - SETE News
Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Biofrontera Inc (BFRI) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Biofrontera Inc (BFRI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Biofrontera Inc (BFRI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Biofrontera Inc (BFRI)’s results reveal risk - US Post News
Biofrontera (NASDAQ:BFRI) Stock Rating Reaffirmed by Benchmark - Defense World
Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Biofrontera Inc. (NASDAQ:BFRI) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Biofrontera reports strong Q2 growth, reduces debt By Investing.com - Investing.com Canada
Earnings call: Biofrontera reports strong Q2 growth, reduces debt - Investing.com
Earnings call: Biofrontera reports strong Q2 growth, reduces debt By Investing.com - Investing.com UK
Biofrontera target cut to $16 from $25 on second-quarter results - Investing.com
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Biofrontera Inc (BFRI) stock analysis: A comprehensive overview - US Post News
Biofrontera Inc (BFRI) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Actinic Keratosis Treatment Industry to Witness Massive Growth - openPR
Biofrontera (BFRI) to Release Quarterly Earnings on Wednesday - Defense World
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce - Simply Wall St
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024 - Yahoo Finance
Photodynamic Therapy Market to Exhibit a Remarkable Growth of USD 39.10 Bn- Theralase Technologies Inc., Biofrontera AG, Holo – La Funcion mx - La Funcion mx
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Biofrontera (NASDAQ:BFRI) Shares Down 7.3% - Defense World
Photodynamic Therapy Market Anticipated to Achieve US$ 8.02 Bn - openPR
Chronic Urticaria Or Hives Drug Market Year 2034|AstraZeneca Plc, Biofrontera AG, ELORAC, Inc., Faes Farma, SA, Genentec – Moose Gazette - Moose Gazette
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable? - Simply Wall St
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable? - Yahoo Finance
Biofrontera Inc. seeks IPO in the USA - Quantisnow
ICYMI: FDA Approves RhodoLED XL Lamp Red Light Source for Use in Actinic Keratosis Treatment - Dermatology Times
FDA-Approved Red-Light LED Lamp Released for Patients With Actinic Keratosis - AJMC.com Managed Markets Network
FDA approves red light LED lamp for patients with actinic keratosis - Medical Dialogues
James Hardie Industries Announces Investor Day By Investing.com - Investing.com
Biofrontera share maintains Buy rating on new lamp launch By Investing.com - Investing.com UK
Biofrontera Unveils RhodoLED® XL Lamp, Eyes Market GrowthTipRanks.com - TipRanks
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp - GlobeNewswire
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp - Morningstar
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp - Markets Insider
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG - br.ADVFN.com
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 94.9% in May - Defense World
$6.97 Billion Photodynamic Therapy Market Outlook, - GlobeNewswire
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun ... - Yahoo Finance
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More - Yahoo Finance
Financial Health Report: Biofrontera Inc (BFRI)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper - Simply Wall St
Roth Capital Comments on Biofrontera Inc.'s Q2 2024 Earnings (NASDAQ:BFRI) - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Q1 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com Australia
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com South Africa
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com India
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com Canada
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com UK
Earnings call: Biofrontera reports Q1 2024 financials amid recovery - Investing.com
Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript - Seeking Alpha
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research
Biofrontera (BFRI) Set to Announce Quarterly Earnings on Wednesday - Defense World
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Panbela Therapeutics (PBLA) Stock Forecast and Price Target 2024 - MarketBeat
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates - MSN
0.32%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):